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Abstract
Background: Early diagnosis of sepsis enables timely resuscitation and antibiotics and prevents subsequent morbidity and
mortality. Clinical approaches relying on point-in-time analysis of vital signs or lab values are often insensitive, non-specific
and late diagnostic markers of sepsis. Exploring otherwise hidden information within intervals-in-time, heart rate variability
(HRV) has been documented to be both altered in the presence of sepsis, and correlated with its severity. We hypothesized
that by continuously tracking individual patient HRV over time in patients as they develop sepsis, we would demonstrate
reduced HRV in association with the onset of sepsis.
Methodology/Principal Findings: We monitored heart rate continuously in adult bone marrow transplant (BMT) patients
(n=21) beginning a day before their BMT and continuing until recovery or withdrawal (1264 days). We characterized HRV
continuously over time with a panel of time, frequency, complexity, and scale-invariant domain techniques. We defined
baseline HRV as mean variability for the first 24 h of monitoring and studied individual and population average percentage
change (from baseline) over time in diverse HRV metrics, in comparison with the time of clinical diagnosis and treatment of
sepsis (defined as systemic inflammatory response syndrome along with clinically suspected infection requiring treatment).
Of the 21 patients enrolled, 4 patients withdrew, leaving 17 patients who completed the study. Fourteen patients
developed sepsis requiring antibiotic therapy, whereas 3 did not. On average, for 12 out of 14 infected patients, a significant
(25%) reduction prior to the clinical diagnosis and treatment of sepsis was observed in standard deviation, root mean
square successive difference, sample and multiscale entropy, fast Fourier transform, detrended fluctuation analysis, and
wavelet variability metrics. For infected patients (n=14), wavelet HRV demonstrated a 25% drop from baseline 35 h prior to
sepsis on average. For 3 out of 3 non-infected patients, all measures, except root mean square successive difference and
entropy, showed no significant reduction. Significant correlation was present amongst these HRV metrics for the entire
population.
Conclusions/Significance: Continuous HRV monitoring is feasible in ambulatory patients, demonstrates significant HRV
alteration in individual patients in association with, and prior to clinical diagnosis and treatment of sepsis, and merits further
investigation as a means of providing early warning of sepsis.
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Introduction
Severe sepsis and septic shock are major causes of mortality and
costs in critically ill patients [1–2]. Acute neutropenia is a frequent
and intended iatrogenic side effect of cytotoxic chemotherapy and
radiotherapy, commonly employed in the management of
malignant hematological diseases, most commonly leukemia and
lymphoma, leading to increasing risk of opportunistic infections
and sepsis [3]. This is particularly apparent in individuals
undergoing induction chemotherapy and bone marrow transplan-
tation (BMT) for acute leukemia due to severe prolonged
neutropenia [4]. Thus, patients undergoing bone marrow
transplantation comprise a group which is at a high risk of
systemic infection (approximately 80%) and mortality (approxi-
mately 5%) [5–6].
Results of a large single-centre randomized trial [7–8] indicate
that, in early septic shock, mortality can be greatly reduced by
employing early goal directed therapy (EGT). In addition, early
effective antibiotic therapy is essential to minimize mortality
secondary to septic shock [9]. Thus, early diagnosis of sepsis
leading to aggressive resuscitation involving antibiotic administra-
tion, and maintaining adequate systemic oxygen delivery and
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diagnosing sepsis are based on an increased absolute value of one
or more vital signs in addition to laboratory tests such as blood
cultures to look for evidence of a pathogen. Although this is the
best clinical approach currently available, it represents a crude and
potentially non-sensitive and non-specific means for early
diagnosis of sepsis.
An alternative approach is to consider the host response to
sepsis as a complex system, and utilize variability analysis as a
means to better characterize the system [10]. Evidence from
experimental and clinical studies indicates that heart rate
variability (HRV) is altered in the presence of systemic infection
[11–13] and correlates with its severity [14–15]. Investigators
studying the prognostic value of HRV have shown it to be an early
predictor of death [16] and multiple organ dysfunction syndrome
(MODS) [17] in adult septic patients. Studies on infants and
neonates have shown HRV to be predictive [18–19] and
diagnostic [20] of sepsis.
For adult patients, prior studies have only assessed HRV for
short intermittent epochs of 5–15 minutes. To our knowledge,
there have been no published attempts to accomplish continuous
HRV analysis in adult patients at high risk of sepsis, and no
comprehensive analysis of HRV has been performed during the
process of development of sepsis. The method that we propose
examines a panel of HRV metrics computed continuously over
time prior to and during the clinical diagnosis of sepsis (defined as
systemic inflammatory response syndrome along with clinically
suspected infection requiring treatment) in patients at high risk for
systemic infection, namely neutropenic patients following bone
marrow transplant. In this pilot study, we demonstrate that (a) it is
feasible to enroll and perform continuous HRV analysis of
prospectively collected non-stationary heart rate (HR) data in
ambulatory patients, (b) continuous variability analysis demon-
strates a reduction in individual patient HRV in association with
the presence of sepsis, and (c) the alteration in HRV occurs within
a clinically relevant period prior to when standard clinical
measures lead to clinical diagnosis and treatment.
Methods
Ethics Statement
Written informed consent was obtained from all participants
and the Ottawa Hospital Research Ethics Board authorized the
study.
Design
This is a descriptive study in which prospective continuous HR
recording, and retrospective analysis of both HRV and change in
HRV were analyzed over time in ambulatory outpatients as they
underwent BMT, and developed neutropenia associated with high
risk for developing systemic infection.
Participants
Our subjects included patients (n=21) undergoing BMT for
hematological malignancy or other disorders (see Table 1) at the
Ottawa Hospital (General Campus), Ontario, Canada. All patients
were enrolled between 05/2007 to 05/2008. Inclusion criteria
included treatment with myeloablative chemoradiotherapy fol-
lowed by an allogeneic or autologous BMT, and informed consent.
Exclusion criteria were pre-existing cardiopulmonary disease,
taking beta-blockers or calcium-channel blockers, pre-existing
arrhythmia (e.g. atrial fibrillation, atrial bigeminy), contraindica-
tion to electrocardiogram adhesives (e.g. allergy, severe psoriasis),
and not being fluent in English or French (which precluded
patients from understanding and signing the informed consent).
Heart Rate (HR) Monitoring
We collected continuous Holter ECG data (average 12 [SD 4]
days of HR monitoring) for all patients in the study, starting
approximately 24 h before their BMT and continuing through
neutropenia until its resolution or until withdrawal from the study.
3M Cavilon spray combined with daily replacement and
relocation of gel ECG electrodes was utilized to reduce any skin
irritation. We used a Zymed DigiTrak-Plus Holter system (Philips
Healthcare, Markham, Ontario, Canada), which annotated all
normal QRS peaks and arrhythmias, including premature atrial
and ventricular beats. Only the beats that characterized normal
sinus rhythm (NSR) were included, while all premature beats were
excluded. RR intervals were derived from R wave annotations.
Thus, for each patient, the input to our signal processing
algorithms comprised time-stamped NSR-based RR intervals in
seconds.
Feasibility
The feasibility measures evaluated included the number of
patients dropping out of the study, the ability of patients to
maintain a diary of clinical events (for example, temperature,
diarrhea, vomiting, etc.), and compliance with Holter HR
monitoring during enrollment. A patient was considered to be
a dropout if he or she enrolled in the study, and subsequently
discontinued Holter HR monitoring (i.e. due to discomfort, or
other factors). Aminimum of 72 h of monitoringwas necessary to
include patients in the study. We examined patient diaries for
Table 1. Study and patient characteristics, along with reason
and type of BMT.
Ottawa (n=17)
Study characteristics
Follow-up (days), median (IQR) 12(9–14)
Clinical diagnosis of sepsis 14(82%)
Admitted to ICU 0
Deaths 0
Patient characteristics
Age (years), median (IQR) 51(46–62)
Women 5(29%)
Diabetes mellitus 1(6%)
History of heart disease 0
Reason for BMT
Chronic idiopathic myelofibrosis 1(6%)
Crohn’s disease 1(6%)
Myelodysplastic syndrome 1(6%)
Non-hematologic malignancy 1(6%)
Leukemia 3(18%)
Myeloma 4(24%)
Lymphoma 6(35%)
Type of BMT
Allogeneic Transport BMT 4(24%)
Autologous BMT 13(76%)
Data are number (%) unless otherwise stated.
doi:10.1371/journal.pone.0006642.t001
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given schedule and instructions. To quantify compliance with
monitoring, we computed a ratio between the total time for
which patients were monitored and the total time of lost data
during the monitoring period. More specifically, percentage of
data lost was computed as DL=100*[T L/(TE2TS)], where DL is
percentage of data lost, TS is monitoring start time, TE is
monitoring end time, and TL is total time of lost data between
TS and TE.
Diagnosis of Sepsis
In this study, sepsis was defined as systemic inflammatory
response syndrome along with clinically suspected infection
requiring treatment. Patients who were administered broad
spectrum antibiotics by the physician (attending hematologist)
were considered to have been clinically diagnosed with sepsis.
Since exact time of diagnosis was uncertain, we assumed the time
(hour and minute) of first administration of antibiotics as the time
of clinical diagnosis of sepsis for consistency in procedure. It was
not possible to identify precisely the actual time of physician
diagnosis. Review of cases and procedures indicated that the
diagnosis preceded the first administration of antibiotics by 30 to
90 minutes. The clinical indication to treat sepsis and the clinical
diagnosis of sepsis are included in Table 2. Over 50% of the
patients had sepsis diagnosed based on the presence of fever,
defined a priori as one recording greater than 38.5 degrees
centigrade or two recordings greater than 38.0 degrees centigrade
within 12 h.
Variability Analysis
We have developed a novel system for continuous individual-
ized multiorgan variability analysis (CIMVA), with single-organ
(the heart) application in this study. The CIMVA system
(developed in Windows
H Matlab
H) comprises algorithms for
computing and visualizing diverse measures of HRV. Details of
diverse HRV measures computed by CIMVA are provided
elsewhere [21], but in Table 3 we present a brief summary.
To accomplish continuous variability analysis over time,
CIMVA employs a moving window approach, whereby a window
(interval-in-time) of user specified width and step marches through
the input signal, computing and time-stamping different variability
metrics at each step, thus making it possible to monitor a change in
HRV over time. A standard RR cleaning algorithm [22] is
Table 2. Indication for antibiotics and bacteriological
diagnosis.
Ottawa (n=14)
Clinical indication for antibiotics
Bacteremia 1(7%)
Productive cough 2(14%)
Mucositis 2(14%)
Clinical suspicion 5(36%)
Fever 7(50%)
Bacteriological diagnosis
Escherichia coli 1(7%)
Streptococcus salivarius 1(7%)
Staphylococcus aureu 1(7%)
Klebsiella pneumoniae 2(14%)
Viridans group streptococcus 2(14%)
Unknown 9(64%)
Data are number (%) unless otherwise stated.
doi:10.1371/journal.pone.0006642.t002
Table 3. Summary of signal analysis capabilities of CIMVA.
Summary
Time Domain
Standard Deviation (SD) Computed as SD=SQRT [(1/N)*SUM(RRi-M)
2], i=1 to N, where RRi is i
th of N inter-beat intervals and M is their mean.
Measures signal variability from its mean value.
Root Mean Square Successive Difference
(RMSSD)
Computed as RMSSD=SQRT[{1/(N-1)}*SUM(RRi-RRi-1)
2], i=2 to N, where RRi is i
th of N inter-beat intervals. Measures
variability of successive signal values.
Complexity Domain
Sample Entropy (SampEn) Computed as negative logarithm of estimate of conditional probability that RR interval epochs of length m that
match pointwise within tolerance r also match at the next point. Characterizes ‘‘meaningful structural richness’’,
information, or disorder of signal.
Multiscale Entropy (MSE) Measures SampEn on multiple timescales. Multiscaling is achieved by averaging non-overlapping samples. Accounts
for dependence of entropy measures on timescale.
Frequency/Time-Frequency Domain
Fast Fourier Transform (FFT) Computed by transforming RR interval signal to frequency domain. AUC of bands (HF: 0.18–0.4 Hz, LF: 0.04–0.15 Hz)
in power spectrum plot characterizes signal variability.
Maximal Overlap Discrete Wavelet Transform
(MODWT)
Computed by transforming RR interval signal to time-frequency domain by convolving it with least asymmetric 8-tap
(LA8) wavelet filter. AUC of spectral density plot characterizes variability (fluctuations) in time and frequency
simultaneously.
Fractal Domain
Detrended Fluctuation Analysis (DFA) Computed as overall root-mean-square fluctuation F(n) of integrated and detrended RR signal on multiple timescales
n. Linear log-log plot of F(n) versus n indicates fractal scaling and AUC (or intercept) and slope characterizes
variability.
Power Law Analysis (PLA) Computed as frequency distribution of squared difference between RR signal and its mean. Linear log-log plot of
frequency versus value indicates fractal scaling and intercept and slope characterizes variability.
doi:10.1371/journal.pone.0006642.t003
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HRV analysis is performed on the cleaned data. The cleaning
algorithm excludes RR intervals less than 0.25 s and greater than
2.5 s, as well as those that differ by more than 15% from the
previous one. The CIMVA system stores the number of samples
lost due to RR cleaning in each window instance, thus keeping
track of signal quality.
We employed a window width of 1200 samples (,10 minutes)
and step of 200 samples (,2 minutes) to compute HRV over time.
In Table 4, we present an example of the output from the CIMVA
system.
Subsequently, the variability time series (HRV over time)
underwent a second data integration step or ‘‘smoothing’’ process.
That is, the change in HRV over time was smoothed utilizing a
moving average and hourly data interpolation technique. This
smoothing approach stabilized the change in variability over time
to characterize long-term behavior of various variability metrics
and facilitated the study of lead times (DTP) for percentage
changes (DHRV) from baseline HRV.
Continuous Analysis
We defined baseline variability as the mean variability for the
first 24 h of recording, prior to transplantation. Given expected
variation in baseline variability from patient to patient, for all
measures of HRV, we computed an individualized percentage change in
variability with respect to the baseline variability (DHRV=100 *
[baseline-current]/baseline). We studied the extent and timing of
DHRV achieved by various metrics for infected and non-infected
patients. To this end, we evaluated individual and between-patient
average DHRV data. We defined a priori a significant DHRV as a
25% loss of variability. We also computed mean population
correlation amongst all diverse HRV measures for the entire
monitoring period.
Results
Monitoring was initiated in 21 patients. Four patients dropped
out within 24 h of initiation of monitoring due to discomfort or
other reasons, leaving 17 (81%) datasets for analysis. We observed
that the requirement for patients to keep a diary of clinical events
on a regular basis was difficult. We found general errors in the
diaries. These included the inability to record the correct time of
the occurrence of an event, and reporting inaccurate frequency
ranges of occurrence of events like vomiting and loose motions.
For n=17 patients who completed the study, for a total
monitoring time of 188 days, 12 days (6%) of data was lost due
to non-compliance to monitoring. The reasons for non-compli-
ance to monitoring included taking off the Holter due to
discomfort or in order to take a bath, or arriving late at the
hospital which led to a delay in attaching a new Holter after the
old one had reached its recording limit. In terms of data quality,
for n=17, for 176 days (monitoring days - lost days of
data=188212=176) of available RR-interval data, the data lost
to RR cleaning was 1.06 days (0.6%).
In the course of a median follow-up of 12 (IQR 9-14, SD 4) days
for n=17, we observed that 14 patients were diagnosed and
treated for sepsis, whereas 3 were not. All patients recovered; no
patient was admitted to the ICU or died. Out of the 14 infected
patients, on an average, 12 (86%) showed a significant (25%) drop
(DHRV) prior to sepsis for standard deviation (SD), root mean
square successive difference (RMSSD), sample entropy (SampEn),
multiscale entropy (MSE) area under curve (AUC), fast Fourier
transform (FFT) low frequency (LF), FFT high frequency (HF),
detrended fluctuation analysis (DFA) AUC, and wavelet spectral
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PLoS ONE | www.plosone.org 4 August 2009 | Volume 4 | Issue 8 | e6642Table 5. Mean population (n=17) correlation amongst diverse HRV measures. Correlations greater than +30% are bolded and
shown in parenthesis.
SD RMSSD
Power Law
Slope
Power Law
Intercept SampEn MSE AUC FFT LF/HF FFT LF FFT HF DFA AUC DFA Alpha
RMSSD (0.61)
Power Law Slope 0.16 20.21
Power Law Intercept (0.73) (0.31) (0.70)
SampEn (0.45) (0.72) 20.22 0.24
MSE AUC (0.39) (0.54) 20.21 0.23 (0.87)
FFT LF/HF 20.07 20.41 0.03 20.02 20.25 20.08
FFT LF (0.61) (0.70) 20.17 (0.33) (0.60) (0.57) 20.02
FFT HF (0.50) (0.84) 20.15 0.26 (0.58) (0.48) 20.43 (0.79)
DFA AUC (0.80) (0.70) 20.14 (0.55) (0.67) (0.67) 20.05 (0.72) (0.57)
DFA Alpha 0.30 20.30 (0.47) (0.51) 20.28 20.25 0.13 20.20 20.23 0.07
Wavelet AUC (0.77) (0.72) 20.17 (0.51) (0.69) (0.68) 20.08 (0.72) (0.58) (0.99) 0.01
doi:10.1371/journal.pone.0006642.t005
Figure 1. Individual smoothed percentage change. ((HRV) in wavelet variability. Individual wavelet (HRV is studied every 1 h in infected (n=14)
and non-infected (n=3) patients from 0 h (time after baseline variability) up to the end of the study. Green plots are non-infected patients whereas
red plots are infected patients. Solid vertical line denotes the time of sepsis. Lead time (TP is studied for 25% drop (dashed vertical line and dot) from
baseline (first 24 h) HRV.
doi:10.1371/journal.pone.0006642.g001
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non-infected patients, all measures, except RMSSD, SampEn and
MSE, showed no significant reduction. Notably, these measures
also showed a substantial correlation (.+30%) amongst each other
(Table 5).
Figure 1 shows the difference in individual patterns of variability
for infected (n=14, red plots) and non-infected (n=3, green plots)
patients for the wavelet measure (AUC) of DHRV. In addition,
Figure 1 shows the timing of a 25% drop in wavelet DHRV
(dashed vertical line and dot) in comparison to the time of sepsis
(solid vertical line for infected patients) for all patients. Except two
patients (Patient #s 4 & 16) out of the 14 infected (n=14, red
plots), all show a 25% drop in DHRV in the neighborhood of
sepsis. For all non-infected patients (n=3, green plots), no 25%
drop was observed in wavelet DHRV. In Figure 1, a positive lead
time DTP means the 25% drop occurred prior to sepsis, a negative
DTP means it occurred after sepsis, and DTP=NaN (not a
number) means no 25% drop occurred. Table 6 summarizes the
lead time (DTP) for all patients (n=17) studied for 25% drop in
DHRV for SD, RMSSD, power law intercept, FFT HF, FFT LF,
DFA, wavelet, SampEn, and MSE metrics of HRV. We note that
except for power law analysis, the 25% drop in DHRV occurs
prior to sepsis (positive DTP) for majority of the infected patients.
Figure 2 shows the difference in average patterns of variability
every 12 h for the infected (n=14) and non-infected (n=3)
population for five diverse HRV measures. For these measures, the
infected population (plotted in red) shows a distinct and continuous
drop in variability from 24–120 h whereas no such drop is
observed for the non-infected population (plotted in green).
Figure 3 shows the mean variation every 6 h in the above diverse
HRV measures zoomed to (72 h around sepsis (time=0 h) for
infected patients (n=14). Plots in Figure 2 and Figure 3 show a
visually evident drop in diverse HRV measures before sepsis; led
by entropy measures, followed by standard deviation, wavelet, and
power law measures of HRV.
Discussion
This study represents a pilot investigation of the methods and
clinical relevance of tracking HRV continuously in high-risk
patients prior to, during, and following clinical diagnosis and
treatment for sepsis. We observed a significant loss (defined as a
25% reduction) in multi-parameter HRV in 12/14 or 86% of
patients treated for sepsis. None of the patients (0/3) without sepsis
demonstrated a significant loss in multi-parameter HRV. Evalu-
ating individual patients as their own control, we observed that the
occurrence of loss of HRV was temporally associated with clinical
diagnosis and treatment of sepsis in individual patients. The onset
of drop of HRV occurred prior to clinical diagnosis and treatment
of sepsis, and importantly, recovery of HRV was observed as the
patients improved (see Figures 1, 2 & 3). Although this study must
be interpreted in light of the small sample size and observational
nature, the temporal association demonstrated in this study
utilizing continuous variability analysis is in keeping with past
Table 6. Lead time DTP (hours) at 25% drop from baseline (first 24 h) HRV.
Non-infected
ID SD RMSSD Power Law FFT HF FFT LF DFA Wavelet SampEn MSE
5 NaN NaN NaN NaN NaN NaN NaN NaN NaN
13 NaN 228 NaN NaN 32 NaN NaN 227 239
15 NaN NaN NaN NaN NaN NaN NaN NaN NaN
Infected
ID SD RMSSD Power Law FFT HF FFT LF DFA Wavelet SampEn MSE
1 69 72 NaN 96 96 7 5 73 72
2 23 156 NaN 32 177 10 8 53 38
3 108 135 NaN 91 97 93 56 130 116
4 47 NaN NaN 6 0 NaN NaN NaN 5
6 68 82 NaN NaN 221 24 220 85 84
77 8 5 211 21 65 2 0 45 65
8 109 110 NaN 68 105 67 63 108 85
9 116 114 18 114 116 109 108 119 118
10 4 7 NaN 9 9 1 0 4 3
11 79 80 NaN 97 97 11 9 82 81
12 138 141 NaN 138 142 122 121 125 127
14 56 80 19 47 79 70 68 78 73
16 227 NaN NaN 235 235 NaN NaN 223 226
17 38 39 NaN 15 39 7 5 16 13
Mean 77.79 91.75 8.67 74.54 88.29 41.25 35.25 87.77 79.00
SD 59.40 42.67 17.04 64.93 69.40 47.41 46.43 56.57 58.47
Observations with NaN excluded for computation of mean and SD.
doi:10.1371/journal.pone.0006642.t006
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reduced HRV was demonstrated in the presence of sepsis in
adults [11–15] and infants [18–20].
For infected patients, we note that DTP values greater than
120 h are probably ‘‘false alarms’’ where the 25% drop does occur
momentarily but is not followed by further sustained drops in
DHRV. For example for Patient #16, the standard deviation
metric shows a DTP of 237 h (Table 6). However, the variability
pattern of standard deviation (not shown) is very similar to that of
the wavelet metric for Patient #16 (Figure 1). This means that
such drops in DHRV cannot be used for prediction of sepsis with
appropriate confidence levels. That is, for infected patients, the
drop in DHRV should be continuous and progressive for the
prediction of sepsis to have more reliability and robustness. We
found that amongst all metrics studied for prediction of sepsis, the
wavelet analysis showed the highest reliability and stability
whereby DTP was within a reasonable timeframe of sepsis, and
‘‘false alarms’’ were minimal with regard to both infected and non-
infected patients (Figure 1 and Table 6). The main reason for the
success of wavelet analysis seems to be the fact that it is a recursive
filtering technique which is capable of analyzing a signal in both
time and frequency domains simultaneously. These attributes
make the wavelet analysis robust to both noise and non-
stationarity in the data, thus allowing it to characterize signal
variability in the most efficient and accurate manner.
While other studies have clearly documented population-based
changes in HRV in association with sepsis, this study identified
individual patient loss of HRV equal to 25% in association with,
and prior to, clinical diagnosis and treatment of sepsis in all but
two patients. Of note, the patient (Patient #16, Figure 1) who
showed no drop in HRV but was diagnosed and treated for sepsis
was a patient with insulin dependent diabetes. This finding
requires further study, in particular since existing literature
suggests that HRV may not be an effective tool for characterizing
the autonomic nervous system control in patients with diabetes
[23–24].
Although this investigation supports the feasibility of long term
HR monitoring (up to 16 days) along with continuous HRV
analysis in non-stationary HR data sets in ambulatory patients, the
use of Holter monitors with gel electrodes proved demanding for
patients recovering from BMT. A total of 4 patients out of 21
(19%) dropped out prematurely after initiating the study. For the
Figure 2. Average percentage change (DHRV) in multi-parameter variability. Average multi-parameter (HRV is studied every 12 h in
infected (n=14) and non-infected (n=3) patients from 0 h (time after baseline variability) up to the end of the study. Green plots are non-infected
patients whereas red plots are infected patients. The error bars represent the standard error mean (SEM). The grey horizontal bar at the bottom
represents the range of hours where sepsis occurred for all infected patients. The blue horizontal line at the bottom represents the mean time
6standard deviation of sepsis for all infected patients.
doi:10.1371/journal.pone.0006642.g002
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non-compliance to monitoring was 6%. We note that some of the
reasons for non-compliance were beyond the control of the
patients. For example, if a patient had to bathe or was in
discomfort, the Holter had to be taken off and sometimes a
particular schedule for arrival at the hospital (resulting in delay in
new Holter attachment and data loss) was based on bed
availability, physician availability, and other similar factors. The
quality of the Holter data recorded was clean and satisfactory; the
data lost to RR cleaning was only 1.06 days (0.6%) in a total of 176
days of RR-interval data. We also visually inspected the recorded
RR-interval data and found it to be satisfactory. We encountered
difficulty in motivating patients to accurately and punctually
maintain a diary of clinical events. This precluded us from
rigorously correlating our HRV measures with other clinical data
such as periodic temperature measurements, symptoms such as
frequency ranges of diarrhea and vomiting, etc.
In 2 out of the 3 normal patients, relatively short Holter
monitoring periods of 3 and 5 days, were observed. This was
because these patients withdrew from the study after these
timeframes. However, these patients did not develop sepsis during
the monitoring period. Thus, they were considered as uninfected
patients for the study.
In order to visually observe and computationally detect changes
in HRV over time, we have pioneered a process of double
temporal integration. The first step of this process involves
computing a moving window based change in HRV over time.
The second step involves smoothing of the change in HRV over
time utilizing the moving average and data interpolation
techniques. We observed that this process was instrumental in
highlighting and studying stable and progressive changes in HRV
hours prior to the onset of sepsis.
In addition to the general process of continuous variability
analysis, we had to evolve the process of continuous individualized
monitoring of individual variability metrics, where no guidelines
exist. For example, in the performance of iteratively repeated
sample and multi-scale entropy analysis, it remains an unanswered
question as to whether the tolerance r, calculated as 15% of the
standard deviation (SD), should be fixed, or continuously re-
calculated based on the changing SD for every window instance.
We empirically observed marked reduction in both entropy metrics
by keeping the tolerance r fixed as 15% of the SD of the first 24 h
Figure 3. Average percentage change (DHRV) in multi-parameter variability around sepsis. Average multi-parameter DHRV is studied
every 6 h in infected (n=14) patients672 h around sepsis (0 h). The error bars represent the standard error mean (SEM).
doi:10.1371/journal.pone.0006642.g003
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oped sepsis. However, re-calculating the entropy metrics based
upon a variable value for r (a new r based on SD of each window
instance), the reduction in entropy was not evident. This highlights
the inter-dependence of the entropy metrics and the time-domain
SD metric and requires further theoretical and empirical study.
We also observed that the DFA AUC and wavelet spectral
density AUC metrics showed identical HRV patterns when
computed continuously over time (99% correlation between
DFA AUC and wavelet spectral density AUC – see Table 5).
Our empirical observation and the correlation analysis highlight
the interdependence between multiple measures of HRV, and the
unresolved debate regarding the most efficient and effective means
to characterize HRV.
The pathophysiology of altered HRV still remains uncertain,
and was not the focus of this study. The loss of overall variation
and complexity metrics are in keeping with existing hypotheses
regarding augmentation of sympathetic tone, ‘‘decomplexifica-
tion’’ of physiologic signals [25], as well as ‘‘uncoupling of biologic
oscillators’’ [26] that have been proposed to occur in association
with sepsis and critical illness. Regardless of the possible
mechanisms, we interpret the alteration in HRV occurring in
association with sepsis as reflective of a fundamental alteration to
the underlying complex system producing the dynamics.
Although this study was not designed for a comprehensive lead-
time analysis, we observed changes in HRV at least 24 h prior to
the clinical diagnosis and treatment of sepsis. This analysis was
limited by the fact that we were unable to identify the precise time
of onset of sepsis, and rather identified the onset of antibiotic
treatment as a temporal point for comparing the results of the
variability analyses. Half of the patients were diagnosed with sepsis
based upon detection of a fever 60–90 minutes prior to
administration of antibiotics. Thus, intermittent sampling of
temperature (about every 6 h) may have delayed diagnosis by
several hours. Of note, we investigated the technology to monitor
skin temperature continuously, and found it imprecise and
unreliable. However, experimental models of sepsis have noted
changes in HRV at least 6 h prior to the onset of fever [27].
Following these results, it will be worthwhile to correlate the
diverse measures of HRV with circulating biomarkers of sepsis and
inflammation. Our study group comprised ambulatory outpatients
recovering from myeloablative therapy, who were already
encumbered by continuous HR monitoring, and frequent blood
sampling was not perceived as ethical in absence of these data.
Numerous unanswered questions remain. Although the clinical
significance of this investigation lies in its logical extension, namely
the potential of utilizing a system of prospective continuous HRV
monitoring to provide an early warning system for sepsis, a larger
validation cohort is clearly required, along with definitive
investigations regarding generalizability, sensitivity and specificity.
It is entirely unclear if hospitalized patients (e.g. surgical or
critically ill patients) will demonstrate such profound loss of HRV
in association with new onset of sepsis. Although a panel of HRV
metrics has been recommended to optimally characterize
variability, it remains to be seen which offer the optimal means
to herald the presence of sepsis. Last, a more in depth evaluation
of lead-time offered by HRV monitoring is warranted. As evident
above from the discussion regarding double temporal integration,
a process of prospective continuous HRV monitoring will
necessarily lead to a delay inherent to the interval of time
necessary to characterize variability and thus the underlying
system. Akin to the uncertainty principle, there is a balance
between the need for an adequate interval of time to characterize
the system, and the need to characterize the system at any point in
time. Optimization of this balance may depend on clinical
applications. Nonetheless, the promise of a novel dimension of
monitoring based on continuous variability analysis is supported
by this observational trial, and merits the attention of future
investigations.
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